Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo

Apogee Therapeutics, Inc.

Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.
Key secondary endpoints: IGA 0/1 46.0%, EASI-90 47.4%, I-NRS≥4 50.5% (all p<0.001).
Safety consistent with class; conjunctivitis rate for mid-dose 10.6% vs 15.1% low and 20.7% high.
Plans to initiate Phase 3 ADventure trials in 2H 2026; also Phase 2b asthma and Phase 2a EoE trials.
Blackstone Life Sciences strategic financing collaboration announced to fund through commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.